Cargando…

Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation

Natural products are ligands and potential inhibitors of Alzheimer’s disease (AD) tau. Dihydromyricetin (DHM) is a CNS active natural product. Despite having signature polyphenolic character, DHM is ostensibly hydrophobic owing to intermolecular hydrogen bonds that shield hydrophilic phenols. Our re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tse, A, Janilkarn-Urena, I, Lin, J, Chang, X, Efthymiou, C, Idrissova, A, Zhang, M, Williams, CK, Magaki, S, Vinters, HV, Davies, DL, Gonen, T, Gukasyan, HJ, Seidler, PM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168350/
https://www.ncbi.nlm.nih.gov/pubmed/37162961
http://dx.doi.org/10.1101/2023.04.25.538327
_version_ 1785038839454105600
author Tse, A
Janilkarn-Urena, I
Lin, J
Chang, X
Efthymiou, C
Idrissova, A
Zhang, M
Williams, CK
Magaki, S
Vinters, HV
Davies, DL
Gonen, T
Gukasyan, HJ
Seidler, PM
author_facet Tse, A
Janilkarn-Urena, I
Lin, J
Chang, X
Efthymiou, C
Idrissova, A
Zhang, M
Williams, CK
Magaki, S
Vinters, HV
Davies, DL
Gonen, T
Gukasyan, HJ
Seidler, PM
author_sort Tse, A
collection PubMed
description Natural products are ligands and potential inhibitors of Alzheimer’s disease (AD) tau. Dihydromyricetin (DHM) is a CNS active natural product. Despite having signature polyphenolic character, DHM is ostensibly hydrophobic owing to intermolecular hydrogen bonds that shield hydrophilic phenols. Our research shows DHM becomes ionized at near-neutral pH allowing formulation of salts with transformed solubility. The MicroED co-crystal structure with trolamine reveals DHM salts as metastable solids with unlocked hydrogen bonding and a thermodynamic bent to solubilize in water. All salt formulations show better inhibitory activity against AD tau than the non-salt form, with efficacies correlating to enhanced solubilities. These results underscore the role of structural chemistry in guiding selection of solubilizing agents for chemical formulation. We propose DHM salts are appropriate formulations for research as dietary supplements to promote healthy aging by combating protein misfolding. Additionally, DHM is a suitable lead for medicinal chemistry and possible development of CNS pharmaceuticals.
format Online
Article
Text
id pubmed-10168350
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-101683502023-05-10 Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation Tse, A Janilkarn-Urena, I Lin, J Chang, X Efthymiou, C Idrissova, A Zhang, M Williams, CK Magaki, S Vinters, HV Davies, DL Gonen, T Gukasyan, HJ Seidler, PM bioRxiv Article Natural products are ligands and potential inhibitors of Alzheimer’s disease (AD) tau. Dihydromyricetin (DHM) is a CNS active natural product. Despite having signature polyphenolic character, DHM is ostensibly hydrophobic owing to intermolecular hydrogen bonds that shield hydrophilic phenols. Our research shows DHM becomes ionized at near-neutral pH allowing formulation of salts with transformed solubility. The MicroED co-crystal structure with trolamine reveals DHM salts as metastable solids with unlocked hydrogen bonding and a thermodynamic bent to solubilize in water. All salt formulations show better inhibitory activity against AD tau than the non-salt form, with efficacies correlating to enhanced solubilities. These results underscore the role of structural chemistry in guiding selection of solubilizing agents for chemical formulation. We propose DHM salts are appropriate formulations for research as dietary supplements to promote healthy aging by combating protein misfolding. Additionally, DHM is a suitable lead for medicinal chemistry and possible development of CNS pharmaceuticals. Cold Spring Harbor Laboratory 2023-04-28 /pmc/articles/PMC10168350/ /pubmed/37162961 http://dx.doi.org/10.1101/2023.04.25.538327 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use.
spellingShingle Article
Tse, A
Janilkarn-Urena, I
Lin, J
Chang, X
Efthymiou, C
Idrissova, A
Zhang, M
Williams, CK
Magaki, S
Vinters, HV
Davies, DL
Gonen, T
Gukasyan, HJ
Seidler, PM
Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
title Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
title_full Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
title_fullStr Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
title_full_unstemmed Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
title_short Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
title_sort improving the solubility of pseudo-hydrophobic alzheimer’s disease medicinal chemicals through co-crystal formulation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168350/
https://www.ncbi.nlm.nih.gov/pubmed/37162961
http://dx.doi.org/10.1101/2023.04.25.538327
work_keys_str_mv AT tsea improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT janilkarnurenai improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT linj improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT changx improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT efthymiouc improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT idrissovaa improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT zhangm improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT williamsck improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT magakis improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT vintershv improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT daviesdl improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT gonent improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT gukasyanhj improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation
AT seidlerpm improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation